• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rallybio Corporation - Common Stock (NQ:RLYB)

15.71 +0.04 (+0.29%)
Streaming Delayed Price Updated: 2:24 PM EDT, Jul 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Rallybio Corporation - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB
June 02, 2026
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Halper Sadeh LLC is Investigating Whether RLYB, KALV, INM, TMHC are Obtaining Fair Deals for their Shareholders
June 02, 2026
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Taylor Morrison Home Corporation (NYSE - TMHC), Rallybio Corporation (Nasdaq – RLYB), InMed Pharmaceuticals, Inc. (Nasdaq – INM), KalVista Pharmaceuticals, Inc.
June 02, 2026
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Price for its Shareholders
June 01, 2026
From Halper Sadeh LLC
Via Business Wire
News headline image
Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement
June 01, 2026
From Rallybio Corporation
Via Business Wire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Terns Therapeutics, Inc. (Nasdaq – TERN), Whitestone REIT (NYSE – WSR), Rallybio Corporation (Nasdaq – RLYB), Day One Biopharmaceuticals, Inc. (Nasdaq - DAWN)
April 09, 2026
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether RLYB, TALK, UNF are Obtaining Fair Deals for their Shareholders
March 19, 2026
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. 
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Rallybio Corporation (Nasdaq – RLYB), SunOpta Inc. (Nasdaq – STKL), Talkspace, Inc. (Nasdaq - TALK), Kennedy-Wilson Holdings, Inc. (Nasdaq - KW)
March 18, 2026
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether TALK, JTAI, RLYB are Obtaining Fair Deals for their Shareholders
March 17, 2026
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB
March 04, 2026
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Deal for its Shareholders
March 02, 2026
From Halper Sadeh LLC
Via Business Wire
News headline image
Rallybio Corporation and Candid Therapeutics Announce Merger Agreement
March 02, 2026
From Candid Therapeutics, Inc.
Via Business Wire
News headline image
Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement
February 17, 2026
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Reverse Stock Split of Common Stock
February 03, 2026
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates
November 06, 2025
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
September 25, 2025
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program
September 03, 2025
From Rallybio Corporation
Via Business Wire
News headline image
Avant Technologies and Ainnova Tech Announce Enhanced Patient Recruitment Strategy Ahead of FDA Clinical Trial
August 12, 2025
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:RLYB),(NASDAQ:BTAI),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 07, 2025
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals
July 08, 2025
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
June 12, 2025
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates
May 08, 2025
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference
April 29, 2025
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT
April 08, 2025
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
March 13, 2025
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Present at the TD Cowen 45th Annual Health Care Conference
February 25, 2025
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial
February 11, 2025
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025
January 10, 2025
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting
December 10, 2024
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025
December 02, 2024
From Rallybio Corporation
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap